drugset / Trial / NCT03729271
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
Phase 4
Completed
148 enrolled
University of Michigan
Commonwealth Diagnostics International, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.
Timeline
- Start
- 2020-01-09
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 550 mg | — |